JP2017532365A - コラーゲンｉｖの置き換え - Google Patents

コラーゲンｉｖの置き換え Download PDF

Info

Publication number
JP2017532365A
JP2017532365A JP2017525311A JP2017525311A JP2017532365A JP 2017532365 A JP2017532365 A JP 2017532365A JP 2017525311 A JP2017525311 A JP 2017525311A JP 2017525311 A JP2017525311 A JP 2017525311A JP 2017532365 A JP2017532365 A JP 2017532365A
Authority
JP
Japan
Prior art keywords
collagen
chain
protein
chimeric
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017525311A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017532365A5 (enExample
Inventor
ローウェル ホッジズ，ブラッドリー
ローウェル ホッジズ，ブラッドリー
マイケル バーンズ，トーマス
マイケル バーンズ，トーマス
レイモンド ライリー，フィリップ
レイモンド ライリー，フィリップ
ユージーン コウトニウク，ウォルター
ユージーン コウトニウク，ウォルター
Original Assignee
ゴールドフィンチ バイオファーマ，インク．
ゴールドフィンチ バイオファーマ，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ゴールドフィンチ バイオファーマ，インク．, ゴールドフィンチ バイオファーマ，インク． filed Critical ゴールドフィンチ バイオファーマ，インク．
Publication of JP2017532365A publication Critical patent/JP2017532365A/ja
Publication of JP2017532365A5 publication Critical patent/JP2017532365A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2017525311A 2014-07-25 2015-07-23 コラーゲンｉｖの置き換え Pending JP2017532365A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462029135P 2014-07-25 2014-07-25
US62/029,135 2014-07-25
US201462072490P 2014-10-30 2014-10-30
US62/072,490 2014-10-30
US201562128729P 2015-03-05 2015-03-05
US62/128,729 2015-03-05
PCT/US2015/041712 WO2016014781A1 (en) 2014-07-25 2015-07-23 Collagen iv replacement

Publications (2)

Publication Number Publication Date
JP2017532365A true JP2017532365A (ja) 2017-11-02
JP2017532365A5 JP2017532365A5 (enExample) 2018-09-06

Family

ID=55163752

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017525311A Pending JP2017532365A (ja) 2014-07-25 2015-07-23 コラーゲンｉｖの置き換え

Country Status (6)

Country Link
US (1) US20180207240A1 (enExample)
EP (1) EP3171889A4 (enExample)
JP (1) JP2017532365A (enExample)
AU (1) AU2015292582A1 (enExample)
CA (1) CA2955481A1 (enExample)
WO (1) WO2016014781A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2021049633A1 (enExample) * 2019-09-11 2021-03-18
JP2023517934A (ja) * 2020-03-12 2023-04-27 ザ ユニバーシティ オブ ブリストル 遺伝子治療

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3496696A4 (en) 2016-08-11 2020-04-22 Sulfilatec, Inc. COMPOUNDS AND METHODS FOR TREATING THE DISEASE.
GB201717301D0 (en) * 2017-10-20 2017-12-06 Nordic Bioscience As Type xvi collagen assay
JP2021532191A (ja) * 2018-07-25 2021-11-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アルポート症候群の治療に使用するためのエンパグリフロジン
CN115004086B (zh) * 2020-02-14 2025-09-26 Tdk株式会社 光调制元件
JP2023551947A (ja) * 2020-12-03 2023-12-13 デルタ ４ ゲーエムベーハー 巣状分節性糸球体硬化症（ｆｓｇｓ）の治療における使用のためのクロピドグレル
CN114149502A (zh) * 2021-12-23 2022-03-08 杭州百凌生物科技有限公司 一种四型胶原蛋白ɑ3的抗体、检测试剂盒及其应用
CN115960211B (zh) * 2022-12-23 2023-11-21 江苏创健医疗科技股份有限公司 一种重组人源ⅵ型胶原蛋白及其制备方法和应用
WO2025193938A1 (en) * 2024-03-13 2025-09-18 Oregon Health & Science University Delivery of type iv collagen alpha chain using a split intein dual aav vector
CN119286901B (zh) * 2024-11-21 2025-09-09 西安巨子生物基因技术股份有限公司 一种重组iv型胶原蛋白及其制备方法和应用
CN120731923B (zh) * 2025-09-05 2025-11-04 内蒙古医科大学附属医院(内蒙古自治区心血管研究所) 一种Alport综合征小鼠NMD逃逸模型的构建方法及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002509895A (ja) * 1998-03-27 2002-04-02 ユニヴァースティ オブ カンザス メディカル センター 細胞および組織相互作用を修飾するためのｉｖ型コラーゲンの単離ドメインの使用
US20030181392A1 (en) * 2002-03-20 2003-09-25 Schnellmann Ricky Gene Uses of collagen IV

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440729B1 (en) * 1995-06-30 2002-08-27 University Of Kansas Medical Center Treating angiogenesis-mediated diseases with the α2 monomer of type IV collagen
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
JP2005504037A (ja) * 2001-07-27 2005-02-10 ユニヴァースティ オブ カンザス メディカル センター Ｉｖ型コラーゲンｎｃ１ドメイン六量体の結晶化構造
US7608413B1 (en) * 2005-03-25 2009-10-27 Celera Corporation Kidney disease targets and uses thereof
WO2011123811A2 (en) * 2010-04-02 2011-10-06 The Board Of Trustees Of The Leland Stanford Junior University Production of post-translationally hydroxylated recombinant proteins in bacteria
UA116639C2 (uk) * 2012-10-09 2018-04-25 Рег'Юлес Терап'Ютікс Інк. Способи лікування синдрому альпорта
US20180055913A1 (en) * 2014-07-29 2018-03-01 Vanderbilt University Recombinant collagen iv surrogates and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002509895A (ja) * 1998-03-27 2002-04-02 ユニヴァースティ オブ カンザス メディカル センター 細胞および組織相互作用を修飾するためのｉｖ型コラーゲンの単離ドメインの使用
US20030181392A1 (en) * 2002-03-20 2003-09-25 Schnellmann Ricky Gene Uses of collagen IV

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIOCHEM BIOPHYS RES COMMUN., vol. 231(1), JPN6019016698, 3 February 1997 (1997-02-03), pages 178 - 82, ISSN: 0004166870 *
KIDNEY INT., vol. 64(6), JPN6019016697, December 2003 (2003-12-01), pages 1986 - 96, ISSN: 0004166869 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2021049633A1 (enExample) * 2019-09-11 2021-03-18
WO2021049633A1 (ja) * 2019-09-11 2021-03-18 国立大学法人熊本大学 難治性遺伝性腎疾患アルポート症候群の根治療法のための薬剤
JP2023517934A (ja) * 2020-03-12 2023-04-27 ザ ユニバーシティ オブ ブリストル 遺伝子治療

Also Published As

Publication number Publication date
EP3171889A4 (en) 2018-03-14
EP3171889A1 (en) 2017-05-31
WO2016014781A1 (en) 2016-01-28
US20180207240A1 (en) 2018-07-26
AU2015292582A1 (en) 2017-02-02
CA2955481A1 (en) 2016-01-28

Similar Documents

Publication Publication Date Title
JP2017532365A (ja) コラーゲンｉｖの置き換え
US20220313830A1 (en) Heparin-peptide bioconjugates and uses thereof
JP5917437B2 (ja) Ａｄｐリボシルトランスフェラーゼ融合バリアントタンパク質
EP2231702A1 (en) Protease inhibitor
JP7214245B2 (ja) 骨関節炎を予防または治療するための方法および薬剤
HK1257583A1 (zh) 预防和治疗脂肪代谢紊乱及其相关病症的药物及其用途
JP7242057B2 (ja) 薬物性腎損傷を予防及び治療するための方法
TW201822790A (zh) 一種預防和治療皮膚纖維化的方法
KR20220127880A (ko) 신경 손상 및 이의 관련 병증 치료 방법
HK1257590A1 (zh) 预防和治疗药物性肾损伤的药物及其用途
HK1257238A1 (zh) 预防和治疗脂质肾损伤的药物及其用途
US20030220253A1 (en) Inhibitors for use in hemostasis
JP7025928B2 (ja) 外科的介入後の腹膜の癒着を予防または治療するための医薬組成物および医薬組成物の使用
JP2022531937A (ja) 筋萎縮性側索硬化症を治療するための方法と薬剤
TWI485157B (zh) 用於抑制血小板凝集之胜肽化合物
JP2009539757A (ja) 血栓溶解活性を有するａｄａｍｔｓ１３含有組成物
HK40010872A (en) Method and drug for preventing or treating osteoarthritis
HK1257235A1 (en) Medicine for treating atherosclerosis and complications of atherosclerosis and use of the medicine
HK1240130A1 (en) Method for preventing or treating radiative and chemical damage
AU2004253185A1 (en) Methods and compositions for treating disorders of the extracellular matrix

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180720

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180720

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190311

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190513

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20191203